TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT05579366: Phase 1/2 Study of Rina-S in Patients With Locally Advanced and/or Metastatic Solid Tumors

Sponsor: Genmab · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 952 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$3,495,030

Rescue Site Savings

+$2,316,930

Unlock Full NCT05579366 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05579366 Rescue Dossier →